Catalent Pharma Solutions has acquired Australian pharmaceutical packaging business Pharmapak Technologies for an undisclosed amount.
The acquisition will allow Catalent to improve its ability to offer integrated solutions to customers.
Go deeper with GlobalData
Pharmapak will provide regional packaging capabilities, which will complement Catalent’s existing facility in Braeside, Victoria, where Catalent produces oral dose products, including softgels, and Vegicaps and OptiShell capsules, for supply throughout Asia Pacific.
Based in New South Wales, Pharmapak offers primary and secondary packaging of oral pharmaceutical dose forms including blisters, bottles and a wide range of tertiary packaging services.
Catalent Asia Pacific president Mark Bisset said: “This acquisition complements our industry-leading oral dosage form development and manufacturing capabilities with a broader range of packaging options, from bulk supply to finished packs.
“Catalent has made substantial recent investments in Asia Pacific with a new facility in China, and last year we celebrated our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity. This latest investment is in response to strong, local market demand for both pharmaceutical, over-the-counter (OTC) and complementary medicine products.”
Pharmapak Technologies will continue to operate with the same name and will also retain approximately 100 employees, including its leadership team at its existing facility in Dee Why, New South Wales.
Catalent employs around 8,500 people across 30 facilities. The company generated more than $1.8bn in annual revenues last year.
